Free Trial

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

Jazz Pharmaceuticals logo
$125.00 +0.41 (+0.33%)
Closing price 04:00 PM Eastern
Extended Trading
$123.50 -1.51 (-1.20%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jazz Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
2
Buy
13

Based on 15 Wall Street analysts who have issued ratings for Jazz Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 2 have given a hold rating, and 13 have given a buy rating for JAZZ.

Consensus Price Target

$181.43
45.14% Upside
According to the 15 analysts' twelve-month price targets for Jazz Pharmaceuticals, the average price target is $181.43. The highest price target for JAZZ is $230.00, while the lowest price target for JAZZ is $147.00. The average price target represents a forecasted upside of 45.14% from the current price of $125.00.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for JAZZ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Jazz Pharmaceuticals and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JAZZ Analyst Ratings Over Time

TypeCurrent Forecast
8/26/24 to 8/26/25
1 Month Ago
7/27/24 to 7/27/25
3 Months Ago
5/28/24 to 5/28/25
1 Year Ago
8/27/23 to 8/26/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
13 Buy rating(s)
11 Buy rating(s)
Hold
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$181.43$181.64$182.79$173.07
Forecasted Upside45.14% Upside53.64% Upside70.81% Upside51.43% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

JAZZ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JAZZ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Jazz Pharmaceuticals Stock vs. The Competition

TypeJazz PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.87
2.79
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside45.62% Upside13,788.07% Upside10.50% Upside
News Sentiment Rating
Positive News

See Recent JAZZ News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/20/2025Needham & Company LLC
2 of 5 stars
Ami Fadia
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$202.00+69.46%
8/15/2025Zacks Research
0 of 5 stars
 UpgradeStrong Sell ➝ Hold
8/6/2025Morgan Stanley
3 of 5 stars
Jeffrey Hung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$165.00 ➝ $162.00+49.83%
7/15/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Hoang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$152.00+36.40%
5/7/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Gregory Renza
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$182.00 ➝ $172.00+68.27%
5/7/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joel Beatty
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$167.00 ➝ $155.00+51.64%
5/7/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Amsellem
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$176.00 ➝ $147.00+40.21%
3/10/2025HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Oren Livnat
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$200.00 ➝ $217.00+56.33%
3/7/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ashwani Verma
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$145.00 ➝ $179.00+31.18%
3/6/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Gregory Fraser
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$220.00 ➝ $230.00+68.12%
2/27/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Balaji Prasad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$190.00 ➝ $200.00+38.73%
2/26/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Charles Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$140.00 ➝ $150.00+3.74%
2/26/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jessica Fye
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$200.00 ➝ $209.00+44.05%
2/13/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mohit Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$130.00 ➝ $170.00+25.52%
11/7/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$200.00 ➝ $195.00+62.80%
6/5/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$169.00+61.75%
3/15/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$225.00 ➝ $230.00+87.04%
9/28/2023Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:31 PM ET.


JAZZ Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Jazz Pharmaceuticals is $181.43, with a high forecast of $230.00 and a low forecast of $147.00.

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" JAZZ shares.

According to analysts, Jazz Pharmaceuticals's stock has a predicted upside of 45.14% based on their 12-month stock forecasts.

Over the previous 90 days, Jazz Pharmaceuticals's stock had 1 upgrade by analysts.

Jazz Pharmaceuticals has been rated by research analysts at Deutsche Bank Aktiengesellschaft, Morgan Stanley, Needham & Company LLC, and Zacks Research in the past 90 days.

Analysts like Jazz Pharmaceuticals more than other "medical" companies. The consensus rating score for Jazz Pharmaceuticals is 2.87 while the average consensus rating score for "medical" companies is 2.79. Learn more on how JAZZ compares to other companies.


This page (NASDAQ:JAZZ) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners